This Generalized Myasthenia Gravis (g MG) - Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Generalized Myasthenia Gravis (gMG) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in thisspace.
Myasthenia gravis (MG) is a disorder of neuromuscular transmission in which autoantibodies bind to acetylcholine receptors that are found in the postsynaptic membrane in the neuromuscular junction, making it difficult to transmit impulses to skeletal muscles and causing weakness. Its prevalence varies between 15 to 179 cases per million and the mortality rate varies between 0.06 to 0.89 per million person-years. This disease is characterized by fluctuating weakness of the voluntary muscles, which worsens with activity and as the day progresses. It is classified as generalized or as ocular.
Generalized Myasthenia Gravis (g MG) - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Generalized Myasthenia Gravis (gMG) pipeline landscape is provided which includes the disease overview and Generalized Myasthenia Gravis (gMG) treatment guidelines. The assessment part of the report embraces, in depth Generalized Myasthenia Gravis (gMG) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Generalized Myasthenia Gravis (gMG) collaborations, licensing, mergers and acquisition, funding, designations and other product relateddetails.
Momenta has developed nipocalimab (M281), a high affinity, fully human, aglycosylated, effectorless IgG1 anti-FcRn monoclonal antibody. In patients with g MG, nipocalimab is expected to improve nerve-to-muscle signals and muscle function, thus alleviating the clinical signs and symptoms of gMG. Nipocalimab has been granted Fast Track and Orphan Drug designation by the FDA in thisindication.
This product will be delivered within 2 business days.
Geography Covered
- Global coverage
Generalized Myasthenia Gravis (g MG)Understanding
Generalized myasthenia gravis (GMG) is a neuromuscular transmission disorder that creates a fluctuating weakness of the voluntary muscles.Myasthenia gravis (MG) is a disorder of neuromuscular transmission in which autoantibodies bind to acetylcholine receptors that are found in the postsynaptic membrane in the neuromuscular junction, making it difficult to transmit impulses to skeletal muscles and causing weakness. Its prevalence varies between 15 to 179 cases per million and the mortality rate varies between 0.06 to 0.89 per million person-years. This disease is characterized by fluctuating weakness of the voluntary muscles, which worsens with activity and as the day progresses. It is classified as generalized or as ocular.
Generalized Myasthenia Gravis (g MG) - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Generalized Myasthenia Gravis (gMG) pipeline landscape is provided which includes the disease overview and Generalized Myasthenia Gravis (gMG) treatment guidelines. The assessment part of the report embraces, in depth Generalized Myasthenia Gravis (gMG) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Generalized Myasthenia Gravis (gMG) collaborations, licensing, mergers and acquisition, funding, designations and other product relateddetails.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence R&D Generalized Myasthenia Gravis (g MG). The therapies under development are focused on novel approaches to treat/improve Generalized Myasthenia Gravis(gMG).Generalized Myasthenia Gravis (g MG) EmergingDrugs
Nipocalimab: Prevention BioMomenta has developed nipocalimab (M281), a high affinity, fully human, aglycosylated, effectorless IgG1 anti-FcRn monoclonal antibody. In patients with g MG, nipocalimab is expected to improve nerve-to-muscle signals and muscle function, thus alleviating the clinical signs and symptoms of gMG. Nipocalimab has been granted Fast Track and Orphan Drug designation by the FDA in thisindication.
Generalized Myasthenia Gravis (g MG): TherapeuticAssessment
This segment of the report provides insights about the Generalized Myasthenia Gravis (g MG) drugs segregated based on following parameters that define the scope of the report, suchas:Major Players in Generalized Myasthenia Gravis (gMG)
There are approx. 10+ key companies which are developing the therapies Generalized Myasthenia Gravis (g MG). The companies which have their Generalized Myasthenia Gravis (gMG) drug candidates in the most advanced stage, i.e preregistration includeRochePhases
This report covers around 10+ products under different phases of clinical development like- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
Generalized Myasthenia Gravis (g MG) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs suchas- Oral
- Intravenous
- Subcutaneous
Molecule Type
Products have been categorized under various Molecule types such as
- Small molecule
- Cell Therapy
- Peptides
- Polymer
- Small molecule
- Gene therapy
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.Generalized Myasthenia Gravis (g MG): Pipeline DevelopmentActivities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Generalized Myasthenia Gravis (g MG) therapeutic drugs key players involved in developing keydrugs.Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Generalized Myasthenia Gravis (g MG)drugs.Generalized Myasthenia Gravis (g MG) ReportInsights
- Generalized Myasthenia Gravis (g MG)Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Generalized Myasthenia Gravis (g MG) ReportAssessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions
Current Treatment Scenario and Emerging Therapies:- How many companies are developing Generalized Myasthenia Gravis (g MG)drugs?
- How many Generalized Myasthenia Gravis (g MG) drugs are developed by eachcompany?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Generalized Myasthenia Gravis (gMG)?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Generalized Myasthenia Gravis (g MG)therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Generalized Myasthenia Gravis (g MG) and theirstatus?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Biocon
- Cartesian Therapeutics
- UCB
- Momenta Pharamaceuticals
- HanAll Biopharma
- Roche
- Alexion
- Novartis
- Takeda
- BioMarin
Key Products
- Descartes 08
- Zilucoplan
- Nipocalimab
- Rozanolixizumab
- Batoclimab
- Satralizumab
- Vemircopan
- Iscalimab
- Mezagitamab
- Amifampridine
This product will be delivered within 2 business days.
Table of Contents
IntroductionExecutive SummaryGeneralized Myasthenia Gravis (gMG)- Analytical PerspectiveDrug profiles in the detailed report…..Drug profiles in the detailed report…..Early Stage Products (Phase I/II)Drug profiles in the detailed report…..Drug profiles in the detailed report…..Generalized Myasthenia Gravis (gMG) Key CompaniesGeneralized Myasthenia Gravis (gMG) Key ProductsGeneralized Myasthenia Gravis (gMG)- Unmet NeedsGeneralized Myasthenia Gravis (gMG)- Market Drivers and BarriersGeneralized Myasthenia Gravis (gMG)- Future Perspectives and ConclusionGeneralized Myasthenia Gravis (gMG) Analyst ViewsGeneralized Myasthenia Gravis (gMG) Key CompaniesList of TablesTable 1 Total Products for Generalized Myasthenia Gravis (gMG)Table 2 Late Stage ProductsTable 3 Mid Stage ProductsTable 4 Early Stage ProductsTable 5 Pre-clinical & Discovery Stage ProductsTable 6 Assessment by Product TypeTable 7 Assessment by Stage and Product TypeTable 8 Assessment by Route of AdministrationTable 9 Assessment by Stage and Route of AdministrationTable 10 Assessment by Molecule TypeTable 11 Assessment by Stage and Molecule TypeTable 12 Inactive Products
Generalized Myasthenia Gravis (gMG): Overview
Pipeline Therapeutics
Therapeutic Assessment
Late Stage Products (Phase III)
Satralizumab: Roche
Mid Stage Products (Phase II)
Vemircopan: Alexion
Descartes 08: Cartesian Therapeutics
Early Stage Products (Phase I)
Drug name: Company name
Inactive Products
Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Biocon
- Cartesian Therapeutics
- UCB
- Momenta Pharamaceuticals
- HanAll Biopharma
- Roche
- Alexion
- Novartis
- Takeda
- BioMarin
